Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has exhibited astonishing efficacy against CD19＋ B-cell malignancies, and is currently the subject of intensive clinical studies as well as others types of research. Autologous CD19CAR-T therapy has demonstrated much greater clinical efficacy against acute lymphocytic leukemia than was expected, whereas its effects against chronic lymphocytic leukemia and malignant lymphoma were weaker than expected. To strengthen the clinical efficacy of CD19CAR-T therapy, its combination with allogeneic hematopoietic stem cell transplantation (allo-HSCT) and CD19CAR-T therapy has started to be examined in clinical trials. The potential advantages of the use of allogeneic T-cells for the generation of CD19CAR-T are as follows: it is easier to produce CD19CAR-T cells with healthy, chemo-naïve T-cells from an allo-HSCT donor and it might have a graft versus leukemia effect that reduces the risk of a relapse. In this review, the possible use of CAR-T therapy in combination with allo-HSCT and current research into CAR-T therapy will be reviewed by giving examples, such as CD19CAR-T and CD123CAR-T therapy.
